Online citations, reference lists, and bibliographies.
← Back to Search

Pemetrexed In The Treatment Of Malignant Mesothelioma: Results From An Expanded Access Program In Germany.

M. Reck, R. Stahel, J. von Pawel, M. Karthaus, S. Korfee, M. Serke, W. Schuette, C. Eschbach, T. Fink, Monika I. Leschinger, C. Manegold
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). Chemonaïve and pretreated patients with inoperable MM of the pleura or peritoneum were eligible. This report describes the results obtained in German centers. Investigators could choose between three treatments: Pemetrexed 500 mg/m(2) alone (P) or in combination with cisplatin 75 mg/m(2) (PC) or carboplatin AUC 5 (PCb). From November 2002 to June 2004, a total of 567 patients (554 with pleural MM; 41% pretreated) were included. Of 548 evaluable patients with pleural MM, 191 received P, 137 PC and 220 PCb. Patients in the P group were more often pretreated (70%) and had worse performance status compared with the other groups. In the P, PC, and PCb groups overall response rate (ORR) was 16%, 24% and 18%, median time to progression (TTP) was 5.5, 8.2, and 6.9 months, and median overall survival (OS) was 8.7, 11.3 and 9.7 months respectively. Efficacy outcomes were better for chemonaïve than for pretreated patients, and P was less hematotoxic than PC or PCb. Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy.
This paper references
Advances in malignant mesothelioma.
B. Robinson (2005)
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
Pemetrexed þ/ platinum for patients with malignant peritoneal mesothelioma: the Bielefeld experience
M Karthaus (2006)
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Malignant peritoneal mesothelioma
K. Bani-Hani (2005)
Comprehensive management of diffuse malignant peritoneal mesothelioma.
P. Sugarbaker (2006)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Malignant mesothelioma.
B. Robinson (2005)
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
[Malignant mesothelioma of the tunica vaginalis].
J. Uría González-Tova (2000)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Malignant Pericardial Mesothelioma. Report of two Cases, Review of the Literature and Differential Diagnosis
M. Papi (2005)
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)

This paper is referenced by
Therapie des nicht-resektablen malignen Pleuramesothelioms
Monika Serke (2011)
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
M. Mencoboni (2017)
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
Preventing recurrence of diffuse malignant peritoneal mesothelioma
Joshua C. Leinwand (2016)
Medical management of mesothelioma
R. Bowman (2011)
Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: a case report and review of the literature
Hana Študentová (2016)
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Y. Nagata (2019)
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
Chapter 13 – Pleura and chest wall
B. Corrin (2011)
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series
Joshua C. Leinwand (2019)
In vitro testing of drug sensitivity in tumor cells from effusion
Carl-Olof Hillerdal (2017)
Case of Malignant Mesothelioma of the Peritoneum and Pleura
Su Jin Lee (2014)
Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.
Yuka Ide (2020)
Das fortgeschrittene Lungenkarzinom
M. Pless (2011)
Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
Vanessa Izquierdo-Sánchez (2018)
Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
Carl-Olof Hillerdal (2017)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
B. Biersack (2018)
Semantic Scholar Logo Some data provided by SemanticScholar